Literature DB >> 32426210

Benign course of COVID-19 in a multiple sclerosis patient treated with Ocrelizumab.

Kulachanya Suwanwongse1, Nehad Shabarek2.   

Abstract

Year:  2020        PMID： 32426210      PMCID： PMC7227515          DOI： 10.1016/j.msard.2020.102201

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN： 2211-0348            Impact factor:   4.339


× No keyword cloud information.
  3 in total

1.  Ocrelizumab infusion experience in patients with relapsing and primary progressive multiple sclerosis: Results from the phase 3 randomized OPERA I, OPERA II, and ORATORIO studies.

Authors:  Lori Mayer; Ludwig Kappos; Michael K Racke; Kottil Rammohan; Anthony Traboulsee; Stephen L Hauser; Laura Julian; Harold Köndgen; Carrie Li; Julie Napieralski; Hanzhe Zheng; Jerry S Wolinsky
Journal:  Mult Scler Relat Disord       Date:  2019-01-28       Impact factor: 4.339

2.  COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?

Authors:  Giovanni Novi; Malgorzata Mikulska; Federica Briano; Federica Toscanini; Francesco Tazza; Antonio Uccelli; Matilde Inglese
Journal:  Mult Scler Relat Disord       Date:  2020-04-15       Impact factor: 4.339

3.  The COVID-19 pandemic and the use of MS disease-modifying therapies.

Authors:  Gavin Giovannoni; Chris Hawkes; Jeannette Lechner-Scott; Michael Levy; Emmanuelle Waubant; Julian Gold
Journal:  Mult Scler Relat Disord       Date:  2020-03-27       Impact factor: 4.339
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.